Therapeutic patents for the treatment of premenstrual syndrome and premenstrual dysphoric disorder: historical perspectives and future directions

Author： Ross Lori E Steiner Meir

Publisher： Informa Healthcare

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.13, Iss.10, 2003-10, pp. : 1491-1499

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Premenstrual dysphoric disorder: is it simply PMS?

By Endicott J.

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 259-259

Elsevier

Access to resources Recommend Favorite

The Role of Central Serotonergic Dysfunction in the Aetiology of Premenstrual Dysphoric Disorder: Therapeutic Implications

By Parry B.L.

CNS Drugs, Vol. 15, Iss. 4, 2001-01 ,pp. : 277-285

Adis International

Access to resources Recommend Favorite

Luteal Phase Administration of Agents for the Treatment of Premenstrual Dysphoric Disorder

By Freeman E.W.

CNS Drugs, Vol. 18, Iss. 7, 2004-01 ,pp. : 453-468

Adis International

Access to resources Recommend Favorite

Treatment of premenstrual dysphoric disorder with luteal phase dosing of sertraline

By Halbreich Uriel Kahn Linda S

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 11, 2003-11 ,pp. : 2065-2078

Informa Healthcare

Access to resources Recommend Favorite

Are there Differential Symptom Profiles that Improve in Response to Different Pharmacological Treatments of Premenstrual Syndrome/Premenstrual Dysphoric Disorder?

By Halbreich Uriel

CNS Drugs, Vol. 20, Iss. 7, 2006-01 ,pp. : 523-547

Adis International

Access to resources Recommend Favorite